Healthcare

INVO Fertility Reminds Shareholders to Cast Their Vote for Upcoming Annual Meeting of Shareholders to be held on Wednesday, June 25, 2025 at 12:00 p.m. Eastern Time

SARASOTA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare…

6 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)

LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…

6 months ago

IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant 

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase…

6 months ago

DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing…

6 months ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected…

6 months ago

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine…

6 months ago

Dr. Anosh Ahmed’s Philanthropic Vision: Empowering Underserved Chicago Communities

Chicago physician and entrepreneur Dr. Anosh Ahmed expands long-term community initiatives focused on healthcare, education, and economic relief through the…

6 months ago

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”…

6 months ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…

6 months ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…

6 months ago